BioMarin Pharmaceutical (BMRN) P/E ratio

P/E ratio · fiscal 2025
33.0×

The P/E ratio of BioMarin Pharmaceutical (BMRN) was 33.0× at the end of fiscal 2025 (December 31, 2025). That is 11.0% higher than the 29.7× of fiscal 2024. Figures as of 18 Nov 2026, 10:29 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/E ratio, fiscal 2025
33.0×
Change on fiscal 2024
+11.0%
Highest on record
138.0×fiscal 2022
Lowest on record
15.6×fiscal 2010
Fiscal years on record
72008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

BioMarin Pharmaceutical P/E ratio, in more detail

Across the 7 fiscal year-ends on record (2008–2025), the highest was 138.0× in fiscal 2022 and the lowest 15.6× in fiscal 2010.

History · 7 fiscal years

P/E ratio at each fiscal year-end

BioMarin Pharmaceutical P/E ratio, year by year

BioMarin Pharmaceutical (BMRN) P/E ratio by fiscal year
Fiscal yearP/E ratioChangeYear endedShare price at year-endDiluted EPS
202533.0× 11.0% up$59.43$1.80
202429.7× 73.2% down$65.73$2.21
2023110.8× 19.7% down$96.42$0.87
2022138.0×—$103.49$0.75
2021——$88.35-$0.35
202019.5×—$87.69$4.50
2019——$84.55-$0.13
2018——$85.15-$0.44
2017——$89.17-$0.67
2016——$82.84-$3.81
2015——$104.76-$1.07
2014——$90.40-$0.92
2013——$70.35—
2012——$49.20-$0.95
2011——$34.38-$0.48
201015.6×—$26.93$1.73
2009——$18.81$0.00
200861.4×—$17.80$0.29

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.

How to read it

It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.

More on BMRN

BioMarin Pharmaceutical, figure by figure

BioMarin Pharmaceutical (BMRN) overview: price, valuation and scorecardAll health care companies by market value

BioMarin Pharmaceutical P/E ratio: questions and answers

What is BioMarin Pharmaceutical's P/E ratio?

The P/E ratio of BioMarin Pharmaceutical (BMRN) was 33.0× at the end of fiscal 2025 (December 31, 2025). That is 11.0% higher than the 29.7× of fiscal 2024.

What are the highest and lowest P/E ratio figures on record for BioMarin Pharmaceutical?

Across the 7 fiscal year-ends on record (2008–2025), the highest was 138.0× in fiscal 2022 and the lowest 15.6× in fiscal 2010.

How is BioMarin Pharmaceutical's P/E ratio calculated?

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E. For BioMarin Pharmaceutical it is on record here for 7 fiscal years, 2008 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “BioMarin Pharmaceutical (BMRN) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/BMRN/pe-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.